Overview

The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes

Status:
RECRUITING
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
The study is being conducted to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of XJN010 Nasal Spray in Patients with Parkinson's Disease Experiencing Off Episodes
Phase:
PHASE2
Details
Lead Sponsor:
Guangzhou Novaken Pharm Co., Ltd.